<DOC>
	<DOC>NCT01704482</DOC>
	<brief_summary>We aim to investigate the efficacy of N-acetylcysteine (NAC) to attenuate acute renal dysfunction in patients with rheumatic valvular heart disease undergoing single valve replacement.</brief_summary>
	<brief_title>N-acetylcysteine for Renal Protection in Patients With Rheumatic Heart Disease Undergoing Valve Replacement</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Rheumatic Diseases</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Heart Valve Diseases</mesh_term>
	<mesh_term>Rheumatic Heart Disease</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>patients with rheumatic heart disease undergoing single valve replacement End stage renal disease (plasma creatinine concentration ≥ 300 µmol/L) Emergency cardiac surgery Planned offpump cardiac surgery Chronic inflammatory disease on immunosuppression Chronic moderate to high dose corticosteroid therapy (≥ 10 mg/day prednisone or equivalent) Age ≤ 18 years.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>